Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
4   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

IPC Welcomes New Councilors Michael Garshick and Andre Ribeiro

Two New Councilors Bring Distinct Perspectives on Psoriatic Disease

The International Psoriasis Council (IPC) welcomes two new Councilors whose work reflects the evolving understanding of psoriatic disease, its systemic impact, and the importance of multidisciplinary, globally informed care.

Michael Garshick and André Ribeiro join IPC’s Council, bringing complementary expertise in cardiovascular comorbidities, psoriatic arthritis, and international clinical education, areas that are increasingly central to improving long-term outcomes for people living with psoriasis.

Michael Garshick, MD

NYU Langone Health

New York, New York, United States

Bio
Dr. Garshick brings a cardiology lens to IPC’s work, focusing on the elevated cardiovascular risk associated with psoriasis and other immune-mediated inflammatory diseases. As a cardiologist with appointments in both medicine and dermatology at NYU Langone Health, his research examines inflammatory mechanisms such as platelet activation and endothelial dysfunction, and he leads an integrated cardio-rheumatology program dedicated to reducing cardiovascular risk in patients with chronic systemic inflammation.

André Lucas Ribeiro, MD

Hospital de Clínicas de Porto Alegre

Porto Alegre, Brazil

Bio
Dr. Ribeiro adds an international and systems-focused perspective, with clinical and research experience spanning Brazil, the United States, and Canada. His work centers on psoriatic arthritis, access to care, and multidisciplinary disease management, and he currently serves as President of Young-GRAPPA (2024–2026), reflecting his commitment to global education and the next generation of clinician leaders.

Strengthening IPC’s Global Perspective

Together, these new Councilors broaden IPC’s expertise across key dimensions of psoriatic disease, supporting the organization’s mission to improve patient outcomes and equip healthcare professionals worldwide with evidence-based, patient-centered guidance.

Categories

Recent Posts

Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints

VIEW

Fellow Perspectives | Psoriasis Care in Ethiopia: Challenges and Opportunities for Progress

VIEW

What Matters Most to People with Psoriasis? IPC Members Help Shape a Global Answer

VIEW

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

Videos Now Available from the IPC Symposium at SID Chicago

Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.

WATCH NOW

Wednesday, June 17, 2026

Take Ten: Mio Nakamura – Psoriasis and Mental Health

Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.

WATCH NOW

Thursday, June 11, 2026